Growth hormone treatment in non-growth hormone-deficient children [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2014 Until 1985 growth hormone (GH) was obtained from pituitary extracts, and was available in limited amounts only to treat severe growth hormone deficiency (GHD).
Sandro Loche +3 more
doaj +3 more sources
The effects of Growth hormone treatment discontinuation in Adults on Metabolic profile, Body composition and quality Of Life (GAMBOL Study) [version 1; peer review: 1 approved, 2 approved with reservations] [PDF]
NIHR Open ResearchBackground In adults, treatment of growth hormone deficiency with daily recombinant human growth hormone injections has shown to improve many clinical features associated with GHD.
Niki Karavitaki +2 more
doaj +2 more sources
New directions in growth hormone treatment in children [PDF]
Pediatric Endocrinology, Diabetes and MetabolismThis paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin,
Renata Stawerska
doaj +2 more sources
TREATMENT OF GROWTH-HORMONE DEFICIENCY WITH GROWTH-HORMONE-RELEASING HORMONE
The Lancet, 1987 18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2. In 12 of the children the height velocity rose on GHRH treatment, and 8 were judged to have shown a worthwhile response to therapy in that their height velocities during the first 6
Ross, R.J.M. +8 more
openaire +5 more sources
Noonan Syndrome, Cancer Risk, and Growth Hormone Treatment [PDF]
JCRPECancer may occur in patients with Noonan syndrome (NS). Review of English literature revealed that myeloproliferative diseases are the most prevalent, followed by intracranial tumours.
Korcan Demir, Kübra Yüksek Acınıklı
doaj +2 more sources
Short-term effect of growth hormone treatment in childhood leukemia survivors with growth hormone deficiency [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 Purpose Survivors of childhood leukemia are at risk of growth impairment due to intensive chemotherapy and radiation treatments. This study investigated the auxological and biochemical characteristics of childhood leukemia survivors diagnosed with growth
Chungwoo Shin +8 more
doaj +1 more source
Molecular Basis for Hypochondroplasia in Japan
Endocrines, 2022 Hypochondroplasia is an autosomal dominant genetic disorder due to a heterozygous pathogenic variant of the FGFR3 gene. The early diagnosis of hypochondroplasia is necessary, since growth hormone is effective for improving adult height.
Tomohiro Ishii +8 more
doaj +1 more source
Growth hormone treatment for growth hormone deficient adults [PDF]
Journal of Clinical Pharmacy and Therapeutics, 1996 Growth hormone (GH) deficiency in adults is now recognized as a clinical syndrome with characteristic signs and symptoms. Numerous trials with daily subcutaneous biosynthetic human growth hormone (hGH) have been conducted in this patient group. Generally, improvements in insulin-like growth factor levels, decreases in total fat mass and increases in ...
W, Clark, M J, Kendall
openaire +2 more sources
Vitamin D and Parathyroid Hormone during Growth Hormone Treatment
Children, 2022 Background. There is some controversy concerning a potential interaction between vitamin D and PTH and the GH/IGF-1 axis. The goal of this study is to assess vitamin D and PTH status in children with GH deficiency at diagnostic and during treatment with ...
Teodoro Durá-Travé +1 more
doaj +1 more source
Growth hormone releasing hormone or growth hormone treatment in growth hormone insufficiency? [PDF]
Archives of Disease in Childhood, 1988 Sixteen prepubertal children who were insufficient for growth hormone were treated with growth hormone releasing hormone (GHRH) 1-40 and GHRH 1-29 for a mean time of nine months (range 6-12 months) with each peptide. Eleven children received GHRH 1-40 in four subcutaneous nocturnal pulses (dose 4-8 micrograms/kg/day) and eight (three of whom were also ...
P J, Smith, C G, Brook
openaire +2 more sources